Status:
COMPLETED
Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Edaravone Dexborneol
Lead Sponsor:
Hui-Sheng Chen
Conditions:
Stroke
Endovascular Thrombectomy
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
To explore the safety and efficacy of edaravone dexborneol for the treatment of acute ischemic stroke patients who received endovascular thrombectomy.
Eligibility Criteria
Inclusion
- 18 to 80 years of age;
- Patients who presented with acute ischemic stroke and a large vessel occlusion in the anterior circulation and met the criteria of mechanical thrombectomy;
- Sufficient recanalization within 9 hours of stroke onset;
- Sufficient recanalization （TICI 2b-3）;
- Acute ischemic stroke with neurological baseline deficit equivalent to the National Institute of Health Stroke Scale (NIHSS) ≥ 6 before recanalization treatment;
- First ever stroke or mRS≤1 after previous disease
- The availability of informed consent.
Exclusion
- Acute ischemic stroke patients with insufficient recanalization（TICI \< 2a）
- Hemorrhagic transformation (PH2) indicated by NCCT performed after the operation immediately;
- Hemorrhagic stroke: cerebral hemorrhage, subarachnoid hemorrhage;
- Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia （ \<100000/mm3）;
- Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;
- Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg);
- Patients with malignant tumor or under antineoplastic therapy with estimated lifetime less than 3 months;
- Pregnancy, plan to get pregnant or during lactation;
- Patients with contraindication or allergic to any ingredient of drugs in our study;
- Unsuitable for this clinical studies assessed by researcher.
Key Trial Info
Start Date :
February 23 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 10 2022
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04667637
Start Date
February 23 2021
End Date
October 10 2022
Last Update
October 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
General Hospital of Northern Theater Command
Shenyang, China, 110840